TGA approves Luxturna gene therapy

In a historical development for the eye health sector, the Therapeutics Goods Administration (TGA) has approved the country’s first true gene therapy, indicated for a rare form of inherited retinal disease (IRD). Read more

Eylea biosimilar embarks on Phase 3 trial

A biopharmaceutical company that is developing cheaper anti-VEGF treatments for Australia and other markets has launched a global clinical trial for a biosimilar version of leading treatment Eylea (aflibercept). Read more

Opthea becomes ASX top 300 company

Melbourne biopharmaceutical company Opthea has announced its inclusion on the ASX 300, just days after its lead drug candidate met primary end points in the latest clinical trial for diabetic macular edema (DME). Read more

Novartis provides safety update for Beovu

A safety review into Novartis’ new anti-VEGF drug Beovu has revealed that reported adverse events are consistent with the approved prescribing information after a group of US retinal specialists linked it to a series of vasculitis cases. Read more